Recruiting studies: Idh1 Idh2 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Phase 3 · 53 location(s) · Hutchmed · NCT06387069 A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) M
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05588141 Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Phase 1 · 1 location(s) · Hutchmed · NCT07025018 Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712 Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
Phase N/A · 1 location(s) · Xiangya Hospital of Central South University · NCT07608003 A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05756777 Diagnostic and Therapeutic Targets in Cartilaginous Tumours
Phase N/A · 1 location(s) · St. Anne's University Hospital Brno, Czech Republic · NCT07315542 A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 · 15 location(s) · Nuvectis Pharma, Inc. · NCT05873686

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.